Mithra Pharmaceuticals S.A.

Equities

MITRA

BE0974283153

Pharmaceuticals

Real-time Euronext Bruxelles 11:35:26 2024-04-26 am EDT 5-day change 1st Jan Change
0.2160 EUR -1.82% Intraday chart for Mithra Pharmaceuticals S.A. -.--% -82.78%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. acquired Neuralis and Estetra from Mithra Pharmaceuticals SA. CI
Mithra Delays AGM Amid Monetization Process MT
Mithra Pharmaceuticals to Postpone the Publication of Its Annual Report 2023 CI
Mithra Pharmaceuticals Obtains Court Protection Measures MT
Mithra Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mithra Pharmaceuticals to Initiate Monetization Process Involving Sale of Assets, Business MT
Mithra Pharmaceuticals Terminates CEO; Names CFO, COO as Successors MT
Mithra Pharmaceuticals SA Announces CEO Changes CI
Mithra Pharmaceuticals Exits Stake in Mayne Pharma MT
An undisclosed buyer acquired a 5.06% stake in Mayne Pharma Group Limited from Mithra Pharmaceuticals SA for AUD 21 million CI
Mithra: share price falls, financial visibility reduced CF
Mithra : Goldman Sachs reduces its stake to below 3%. CF
Mithra Pharmaceuticals Completes Pediatric Study of Contraceptive Product in Adolescent Women MT
Mithra Signs Agreement with Gedeon Richter for Commercialization of Estelle, Donesta in China MT
Mithra Pharmaceuticals SA and Gedeon Richter Plc. Signs Binding Head of Terms to Commercialize Estelle and Donesta in China CI
Mithra Pharmaceuticals to Conduct Additional Data Analysis for Menopause-candidate Drug MT
Certain Ordinary Shares of Mithra Pharmaceuticals SA are subject to a Lock-Up Agreement Ending on 26-NOV-2023. CI
Mithra Pharmaceuticals Obtains US Patent for Contraceptive Pill MT
Mayne Pharma Gets Additional US Patent for Contraceptive MT
Mithra and Searchlight Pharma Sign DONESTA Licensing Agreement for Canada CI
Mithra Pharmaceuticals Signs License Agreement for Menopause Drug With Canada's Searchlight Pharma MT
Mithra and Searchlight Pharma Inc. Signs License and Supply Agreement for the Canadian Rights to DONESTA CI
Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump MT
Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen at NAMS 2023 CI
Mithra Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Chart Mithra Pharmaceuticals S.A.
More charts
Logo Mithra Pharmaceuticals S.A.
Mithra Pharmaceuticals SA is a Belgian biopharmaceutical company dedicated to transforming women's health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra Pharmaceuticals S.A. explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrolbased product in 2021, the contraceptive pill ESTELLE®, Mithra is now focusing on its second product DONESTA®, the next-generation hormone therapy. Mithra Pharmaceuticals S.A. also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO.
Employees
270
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
0.2160EUR
Average target price
0.1000EUR
Spread / Average Target
-53.70%
Consensus

Annual profits - Rate of surprise